HZNP News and Press, Horizon Therapeutics Public Limited Company From 11/04/22

Horizon Therapeutics ( NASDAQ: HZNP ) ticked up 0.3%, quickly paring an earlier decline, on speculation that the company may be the target of an activist after a 13-F filing. Barclays added 3.56 million shares in 3Q, up from 288K in the prior quarter, Dealreporter ...

Horizon Therapeutics (NASDAQ: HZNP) , a biopharmaceutical company that specializes in rare, autoimmune, and inflammatory diseases, saw its shares jump 11.32% on Wednesday after the company released its third-quarter earnings. The stock closed on Tuesday at $63.18, then opened at $68...

Summary Horizon beat the Q3 EPS and revenue consensus. Tepezza reported modest growth and investor fears of sales falling off a cliff have not materialized. The company increased the peak sales guidance for Tepezza and Krystexxa by $500 million each. Positive phase 2 resul...

Horizon Therapeutics Public Limited Company (HZNP) Q3 2022 Results Conference Call November 2, 2022 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive Officer ...

Horizon Therapeutics ( NASDAQ: HZNP ) gained ~8% pre-market Wednesday after announcing better-than-expected financials for Q3 2022 and raising the full-year outlook on the back of solid demand for Krystexxa, a treatment indicated for arthritic condition, gout. Howeve...

Horizon Therapeutics press release ( NASDAQ: HZNP ): Q3 Non-GAAP EPS of $1.25 beats by $0.24 . Revenue of $925.4M (-10.2% Y/Y) beats by $37.76M . Full-Year 2022 Guidance and Peak Annual Net Sales Expectations : Increasing Full-Year 2022 Net Sales Guida...

Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones Expenses -- -- TEPEZZA ® (teprotumumab-trbw) Net ...

Summary My portfolio, built specifically for my retirement ~20+ years from now, invested a new large position in a beaten down big tech stock. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a...

Summary Having suffered through a sharp decline in earnings multiples, SMID cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings t...

--Company Recognized for Transparency and Best Practices Related to an Inclusive Culture-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named to Seramount’s (formerly Working Mother media) 2022 Inclusion Index. The Inclusion Index recognizes com...